United States · FDA National Drug Code directory

Ondansetron

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
50090-1658_7e052bf8-036e-4239-a013-f7d21537ba5c
Product NDC
50090-1658
Form
TABLET, ORALLY DISINTEGRATING
Composition / generic term
Ondansetron
Labeler
A-S Medication Solutions
Marketing category
ANDA
Marketing start / end (source format)
20070627
Source listing expiry
20271231

Source-listed ingredients

  • ONDANSETRON — 4 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 1 BLISTER PACK in 1 PACKET (50090-1658-0) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · 50090-1658-0
  • 1 BLISTER PACK in 1 PACKET (50090-1658-1) / 20 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · 50090-1658-1
  • 1 BLISTER PACK in 1 PACKAGE (50090-1658-2) / 5 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · 50090-1658-2
  • 30 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (50090-1658-3) · 50090-1658-3

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →